The study is recruiting HIV/HCV coinfected people with genotype 1 through 6 to determine the safety and effectiveness of the combination of ABT-493 plus ABT-530. The study is enrolling non-cirrhotic patients who will be treated for 8 weeks and compensated cirrhotic patients who will be treated for 12 weeks. In the completed Phase II studies the combination cured 97% to 100% of HCV genotype 1, 2 and 3 patients.
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) (EXPEDITION-2)
To view the entire study description click here
Share This Page